TCR² Therapeutics Inc.

📍 Cambridge, United States🗓 Founded 2015👥 88 employees💰 Last funded Feb 2021
Biotechnology🌐 tcr2.com
Website LinkedIn
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in TCR² Therapeutics Inc.?
TCR² Therapeutics Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did TCR² Therapeutics Inc. last raise funding?
The most recent investment in TCR² Therapeutics Inc. recorded on gritt.io was in February 2021.
When was TCR² Therapeutics Inc. founded?
TCR² Therapeutics Inc. was founded in 2015.
What industry is TCR² Therapeutics Inc. in?
TCR² Therapeutics Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is TCR² Therapeutics Inc. based?
TCR² Therapeutics Inc. is headquartered in Cambridge, United States.